One of the most important factors behind resistance evolution in malaria is the failure to deliver sufficiently high amounts of drugs to early stages of Plasmodium-infected red blood cells (pRBCs). Despite having been considered for decades as a promising approach, the delivery of antimalarials encapsulated in immunoliposomes targeted to pRBCs has not progressed towards clinical applications, whereas in vitro assays rarely reach drug efficacy improvements above 10-fold. Here we show that encapsulation efficiencies reaching N96% are achieved for the weak basic drugs chloroquine (CQ) and primaquine using the pH gradient loading method in liposomes containing neutral saturated phospholipids. Targeting antibodies are best conjugated through the...
The adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drugs, targeting mole...
Combination therapies, where two drugs acting through different mechanisms are administered simultan...
The adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drugs, targeting mole...
One of the most important factors behind resistance evolution in malaria is the failure to deliver s...
Most drugs currently entering the clinical pipeline for severe malaria therapeutics...
Bearing in mind the absence of an effective preventive vaccine against malaria (WHO, 2015) and its s...
[eng] Bearing in mind the absence of an effective preventive vaccine against malaria (WHO, 2015) an...
Bearing in mind the absence of an effective preventive vaccine against malaria (WHO, 2015) and its s...
Most drugs currently entering the clinical pipeline for severe malaria therapeutics ...
The suitability of liposomes as drug carriers in the treatment of drug-resistant rodent malaria was ...
Among several factors behind drug resistance evolution in malaria is the challenge of administering...
The adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drug...
Combination therapies, where two drugs acting through different mechanisms are administered simultan...
Combination therapies, where two drugs acting through different mechanisms are administered simultan...
The adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drug...
The adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drugs, targeting mole...
Combination therapies, where two drugs acting through different mechanisms are administered simultan...
The adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drugs, targeting mole...
One of the most important factors behind resistance evolution in malaria is the failure to deliver s...
Most drugs currently entering the clinical pipeline for severe malaria therapeutics...
Bearing in mind the absence of an effective preventive vaccine against malaria (WHO, 2015) and its s...
[eng] Bearing in mind the absence of an effective preventive vaccine against malaria (WHO, 2015) an...
Bearing in mind the absence of an effective preventive vaccine against malaria (WHO, 2015) and its s...
Most drugs currently entering the clinical pipeline for severe malaria therapeutics ...
The suitability of liposomes as drug carriers in the treatment of drug-resistant rodent malaria was ...
Among several factors behind drug resistance evolution in malaria is the challenge of administering...
The adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drug...
Combination therapies, where two drugs acting through different mechanisms are administered simultan...
Combination therapies, where two drugs acting through different mechanisms are administered simultan...
The adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drug...
The adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drugs, targeting mole...
Combination therapies, where two drugs acting through different mechanisms are administered simultan...
The adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drugs, targeting mole...